However, it notes that safety issues concerning on the two multiple sclerosis drugs remain its main concern, since it is nearly available in the market.EBSCO_bspPharmawatch Monthly Review
Multiple Sclerosis (MS) is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body.
In recent years, with the extensive research on the pathological mechanism and molecular mechanism of DKD, there are more and more new drugs based on this, such as new hypoglycemic drugs sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) inhibitors, and ...
Two new drugs hold promise for the treatment of symptoms associated with multiple sclerosis Screening healthy persons for common cancers has taken one step closer to reality More than one in three children have been victims of abuse in the past year News High sodium intake is not an osteo...
Ever since the introduction of the first disease modifying therapies, the concept of multiple sclerosis treatment algorithms developed ceaselessly. The increasing number of available drugs is paralleled by impelling issue of ensuring the most appropriate treatment to the right patient at the right time....
First published on MedCityNews.com. In the latest pharma-academia partnership, Genzyme and Cleveland Clinic researchers will align their efforts to better understand and treat multiple sclerosis. First published on MedCityNews.com. In the latest pharma-a
Mitoxantrone: a review of its use in multiple sclerosis Mitoxantrone (Novantrone), a synthetic anthracenedione derivative, is an antineoplastic, immunomodulatory agent. Its presumed mechanism of action in patien... LJ Scott,DP Figgitt - 《Cns Drugs》 被引量: 149发表: 2004年 Mitoxantrone (Novantr...
For decades, work in the field has focused on targeting one component of the immune system – the T cells – which were always seen as the "smoking gun" of the disease because they attack nerve fibers in the brain, causing the lesions and ultimately the symptoms of multiple sclerosis. Ocre...
The FDA said it approved Tecfidera based on two studies showing patients taking the drug had fewer relapses than patients taking a dummy pill. The approval gives Biogen a new product in an increasingly crowded field of multiple sclerosis drugs. The biotech drugmaker already sells the once-a-wee...
Multiple sclerosis is a common human demyelinating disease of the central nervous system (CNS), and it is thought to involve autoimmune responses to CNS my... JL Croxford,SD Miller - 《Drugs of Today》 被引量: 33发表: 2004年 Symptomatic treatment and management of multiple sclerosis. Multiple...